Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166)
about
Rational development of addiction pharmacotherapies: successes, failures, and prospectsReward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviorsCocaine-predictive stimulus induces drug-seeking behavior and neural activation in limbic brain regions after multiple months of abstinence: reversal by D(1) antagonistsLack of self-administration of cocaine in dopamine D1 receptor knock-out miceThe dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers.Drug-induced activation of dopamine D(1) receptor signaling and inhibition of class I/II histone deacetylase induce chromatin remodeling in reward circuitry and modulate cocaine-related behaviorsBehavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective.Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in ratsAnti-relapse medications: preclinical models for drug addiction treatment.The reinstatement model and relapse prevention: a clinical perspective.Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence.Dopamine D1 and D3 receptors mediate reconsolidation of cocaine memories in mouse models of drug self-administrationPharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.Prolonged attenuation of the reinforcing strength of cocaine by chronic d-amphetamine in rhesus monkeysThe role of brain emotional systems in addictions: a neuro-evolutionary perspective and new 'self-report' animal model.Diminished role for dopamine D1 receptors in cocaine addiction?Stimulation of dopamine D2/D3 but not D1 receptors in the central amygdala decreases cocaine-seeking behaviorPharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapseToward a model of drug relapse: an assessment of the validity of the reinstatement procedure.Mood-elevating effects of d-amphetamine and incentive salience: the effect of acute dopamine precursor depletion.Clinical neuropharmacology of drugs of abuse: a comparison of drug-discrimination and subject-report measures.Infecting the brain to stop addiction?A qualitative and quantitative review of cocaine-induced craving: the phenomenon of priming.CRF antagonism within the ventral tegmental area but not the extended amygdala attenuates the anxiogenic effects of cocaine in rats.Comparison of dopamine D1 and D5 receptor knockout mice for cocaine locomotor sensitization.Controversies in translational research: drug self-administration.Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112Pharmacogenetic treatments for drug addiction: alcohol and opiates.Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls.The dopamine antagonist cis-flupenthixol blocks the expression of the conditioned positive but not the negative effects of cocaine in rats.Nicotinic receptors and stages of nicotine dependence.Convergence of dopamine and glutamate signaling onto striatal ERK activation in response to drugs of abuse.Morphine responsiveness to thermal pain stimuli is aging-associated and mediated by dopamine D1 and D3 receptor interactions.Modulation of Dopaminergic Pathways to Treat Erectile Dysfunction.c-Fos is an intracellular regulator of cocaine-induced long-term changes.Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine.D1-receptor drugs and cocaine-seeking behavior: investigation of receptor mediation and behavioral disruption in rats.Effects of Acute and Chronic Treatments with Dopamine D2 and D3 Receptor Ligands on Cocaine versus Food Choice in Rats.The dopamine D1 antagonist reduces ethanol reward for C57BL/6 mice.
P2860
Q27025533-4DDA23E9-4002-48AF-B325-A60DB7D0E93EQ28209521-6C681864-9F62-4366-825E-ECAB84AC1463Q28348765-03160956-A150-4CE3-85A3-96D297548CC9Q28511866-CE46F9F3-065E-4D90-A7EB-6BFEA0A09519Q30471555-CF0F2875-F924-4029-8F06-B061AA5E2B36Q30490304-8CDFD182-1C87-46BE-A305-5AAF4BB66B80Q30492329-B2D2881F-8A08-4919-9F37-E6F32AF76071Q33748306-F2D28B3B-700A-462A-8793-A28E4D3142F3Q33927470-FAE1FE79-6D20-4F1A-99F9-E44EB170AE16Q34062912-B519840B-12C4-438C-B582-BEB8017DB7C9Q34200260-B5FBDEC8-BA78-42F8-AEAC-43293160658FQ34231896-BC0BE47F-38CE-48AB-B726-9A82C74F3F2CQ34253787-6D6A05F0-B9E0-4503-9BB1-272923E8CD5BQ34423583-D4A12C92-9081-44F3-A362-B98E3816358CQ34522538-14659924-A383-4CF6-83DE-00187155A5A6Q34543222-A7D25C75-DC18-4E3C-9937-9834D5F19242Q34768667-6357CD23-247D-4227-A7FB-CF81F9C098FBQ34982551-EB92BFD5-38F8-40B6-89F7-51AF49D86E7BQ35062881-D5FA45F5-84AD-44B7-A3F4-BD891C1773C4Q35103785-CC157343-EF28-4932-BAFF-C5DAD0186693Q35664118-B0C3C8FD-E211-4D68-9523-4F7FB170F5F7Q35684589-0A1CB4E8-FA44-4FC7-9052-01FED21E62E3Q35847447-B3A79559-91E6-4A46-961C-DAA892CFE018Q35870406-15E2ADEA-288F-422C-A51F-37F2A99B6C5CQ36218003-7378A68A-EB75-4258-BB01-CAC1BB06FB8BQ36981184-E6172BB8-F45D-464F-8F52-4A86C4BE0A2BQ37087986-7C537EA6-1100-4AF6-8D26-7F0F59AE59E5Q37130593-4F8BB2B4-DE6F-4503-BF79-9708039BE1C9Q37201611-81B14F0F-E0CE-4BF2-B501-C0BD32C7B2F2Q37294513-175FE234-E557-4180-A2F1-E670BC25E38FQ37351052-160BBE6D-D2DA-4C43-A86A-62E6E90066CBQ37404292-E14508FD-3EC1-48FE-8098-9C0591E1B8E7Q38177261-59E36F8B-A759-4988-AB68-03071853178CQ38930685-CEBA5751-B689-45D3-9A09-A8D68FA8E6E1Q38931983-1CEE5F0D-770B-4E45-B427-0C2746434FB5Q41191508-68D399F8-660B-4E28-8ED4-7FE230FA327EQ42841373-4C64C17E-D170-4881-80E0-8D25CF0FECA2Q44273583-95589822-33DD-4B43-ADFA-49FB6F38DE17Q45058435-0DBF5342-7A65-4769-9113-B953E7F88862Q45152841-0FA45A15-322B-42D2-BECB-88B6E5CDFE42
P2860
Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166)
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Attenuation of the euphoric ef ...... ntagonist ecopipam (SCH 39166)
@ast
Attenuation of the euphoric ef ...... ntagonist ecopipam (SCH 39166)
@en
Attenuation of the euphoric ef ...... ntagonist ecopipam (SCH 39166)
@nl
type
label
Attenuation of the euphoric ef ...... ntagonist ecopipam (SCH 39166)
@ast
Attenuation of the euphoric ef ...... ntagonist ecopipam (SCH 39166)
@en
Attenuation of the euphoric ef ...... ntagonist ecopipam (SCH 39166)
@nl
prefLabel
Attenuation of the euphoric ef ...... ntagonist ecopipam (SCH 39166)
@ast
Attenuation of the euphoric ef ...... ntagonist ecopipam (SCH 39166)
@en
Attenuation of the euphoric ef ...... ntagonist ecopipam (SCH 39166)
@nl
P2093
P1433
P1476
Attenuation of the euphoric ef ...... ntagonist ecopipam (SCH 39166)
@en
P2093
C P O'Brien
E M Sellers
H L Kaplan
M K Romach
P304
P356
10.1001/ARCHPSYC.56.12.1101
P407
P50
P577
1999-12-01T00:00:00Z